JP2025507595A5 - - Google Patents
Info
- Publication number
- JP2025507595A5 JP2025507595A5 JP2024548670A JP2024548670A JP2025507595A5 JP 2025507595 A5 JP2025507595 A5 JP 2025507595A5 JP 2024548670 A JP2024548670 A JP 2024548670A JP 2024548670 A JP2024548670 A JP 2024548670A JP 2025507595 A5 JP2025507595 A5 JP 2025507595A5
- Authority
- JP
- Japan
- Prior art keywords
- omicron
- antibody
- cov
- sars
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2202232.1 | 2022-02-18 | ||
| GBGB2202232.1A GB202202232D0 (en) | 2022-02-18 | 2022-02-18 | Antibodies |
| GB2203423.5 | 2022-03-11 | ||
| GBGB2203423.5A GB202203423D0 (en) | 2022-03-11 | 2022-03-11 | Antibodies |
| GB2206777.1 | 2022-05-09 | ||
| GB202206777 | 2022-05-09 | ||
| GB2212470.5 | 2022-08-26 | ||
| GBGB2212470.5A GB202212470D0 (en) | 2022-08-26 | 2022-08-26 | Antibodies |
| GB2214036.2 | 2022-09-26 | ||
| GBGB2214036.2A GB202214036D0 (en) | 2022-09-26 | 2022-09-26 | Antibodies |
| GB2215418.1 | 2022-10-18 | ||
| GBGB2215418.1A GB202215418D0 (en) | 2022-10-18 | 2022-10-18 | Antibodies |
| GBGB2301959.9A GB202301959D0 (en) | 2023-02-10 | 2023-02-10 | Antibodies |
| GB2301959.9 | 2023-02-10 | ||
| PCT/EP2023/054109 WO2023156636A1 (en) | 2022-02-18 | 2023-02-17 | Antibodies capable of binding to the spike protein of coronavirus sars-cov-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507595A JP2025507595A (ja) | 2025-03-21 |
| JP2025507595A5 true JP2025507595A5 (https=) | 2026-02-24 |
Family
ID=86497315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548670A Pending JP2025507595A (ja) | 2022-02-18 | 2023-02-17 | コロナウイルスＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に結合することができる抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250154231A1 (https=) |
| EP (1) | EP4479425A1 (https=) |
| JP (1) | JP2025507595A (https=) |
| KR (1) | KR20240142594A (https=) |
| CN (1) | CN119403828B (https=) |
| AU (1) | AU2023220851A1 (https=) |
| CA (1) | CA3252608A1 (https=) |
| CO (1) | CO2024012622A2 (https=) |
| CR (1) | CR20240389A (https=) |
| GB (1) | GB2614651B (https=) |
| IL (1) | IL315020A (https=) |
| MX (1) | MX2024010178A (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250289871A1 (en) | 2022-04-29 | 2025-09-18 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
| GB202316016D0 (en) * | 2023-10-19 | 2023-12-06 | Univ Oxford Innovation Ltd | Antibodies |
| CN121471347B (zh) * | 2026-01-12 | 2026-03-27 | 中国人民解放军军事科学院军事医学研究院 | 一种抗SARS-CoV和SARS-CoV-2的全人源单克隆抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250107297A (ko) * | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| MX2021015024A (es) * | 2020-04-28 | 2022-01-18 | Univ Rockefeller | Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos. |
| WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| WO2021229561A1 (en) * | 2020-05-14 | 2021-11-18 | The Israel Institute of Biological Research (IIBR) | Anti-sars-cov-2 antibodies |
-
2023
- 2023-02-17 JP JP2024548670A patent/JP2025507595A/ja active Pending
- 2023-02-17 EP EP23707291.3A patent/EP4479425A1/en active Pending
- 2023-02-17 CR CR20240389A patent/CR20240389A/es unknown
- 2023-02-17 CA CA3252608A patent/CA3252608A1/en active Pending
- 2023-02-17 GB GB2305426.5A patent/GB2614651B/en active Active
- 2023-02-17 AU AU2023220851A patent/AU2023220851A1/en active Pending
- 2023-02-17 IL IL315020A patent/IL315020A/en unknown
- 2023-02-17 CN CN202380034355.XA patent/CN119403828B/zh active Active
- 2023-02-17 US US18/839,067 patent/US20250154231A1/en active Pending
- 2023-02-17 KR KR1020247030884A patent/KR20240142594A/ko active Pending
-
2024
- 2024-08-19 MX MX2024010178A patent/MX2024010178A/es unknown
- 2024-09-17 CO CONC2024/0012622A patent/CO2024012622A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025507595A5 (https=) | ||
| JP2023061927A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| JP2023549067A5 (https=) | ||
| IL295310A (en) | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) | |
| JP6105146B2 (ja) | Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体 | |
| JP6979875B2 (ja) | チクングニヤウイルスの抗体媒介性中和 | |
| WO2021254481A1 (zh) | 抗Claudin18.2抗体以及其用途 | |
| JP2019516348A (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| JP2011501656A5 (https=) | ||
| TW201922792A (zh) | Cd96 抗體、其抗原結合片段及醫藥用途 | |
| JP2021509274A (ja) | モノクローナル抗体およびその使用法 | |
| JP2005528914A5 (https=) | ||
| US20230331834A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) | |
| CN114591434A (zh) | 抗Siglec15抗体及其制备方法和用途 | |
| KR20250039330A (ko) | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자 | |
| EP4206224A1 (en) | Human antibody or antigen-binding fragment thereof against coronavirus spike protein | |
| US12497449B2 (en) | Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists | |
| JP2006501283A (ja) | ＬＦＡ−１αサブユニット抗体と利用方法 | |
| WO2022143815A1 (zh) | 抗新冠病毒受体结合区域表位中和抗体及其应用 | |
| CN118206657B (zh) | 一种半乳糖凝集素-3的抗体及其应用 | |
| CN104861068B (zh) | 一种全人源抗her3抗体及其治疗相关疾病的用途 | |
| WO2024053719A1 (ja) | コロナウイルス変異株に対するヒト抗体またはその抗原結合断片 | |
| JP2025516723A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法 | |
| CN115337396A (zh) | 一种全人源单克隆抗体组合及其应用 |